politics

Moderna and Merck's personalized cancer vaccine shows promise in melanoma trial

19 Ağustos 2026CNBC

A personalized cancer vaccine developed by Moderna and Merck has shown promising results in its first late-stage trial for melanoma. The combination treatment significantly prolonged the duration patients lived without their melanoma returning, outperforming the existing treatment Keytruda alone.
This advancement could represent a significant step forward in melanoma treatment options.
Melanoma is one of the most aggressive forms of skin cancer, and existing treatments like Keytruda have limitations. The introduction of personalized vaccines represents a shift towards more targeted therapies that could improve survival rates and quality of life for patients.
The results from this trial highlight the potential of personalized medicine in oncology, particularly in tailoring treatments to individual patient profiles. By combining a novel vaccine approach with established immunotherapy, the study underscores the importance of innovative strategies in enhancing patient outco…

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.